Products for Research Use Only

RIPK1-IN-17

CAT: 0804-HY-157039-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-157039-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS) [1].
CAS Number
3033385-59-7
UNSPSC
12352005
Target
Mixed Lineage Kinase; Necroptosis; RIP kinase
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ripk1-in-17.html
Purity
98.38
Solubility
10 mM in DMSO
Smiles
O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC2=C(C=CC(C3=CC=C4N=C(SC4=C3)NC(C5CC5)=O)=C2)F
Molecular Formula
C26H19F4N3O3S
Molecular Weight
529.51
References & Citations
[1]Fang JJ, et al. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity. J Med Chem. 2023 Nov 2.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1